Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 21;9:5435. doi: 10.1038/s41467-018-07825-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Treatment with ABT-737 increases median lifespan of progeroid mice with perforin deficiency. LMNA^+/G609G/Prf1^−/− mice, LMNA^+/G609G/Prf1^+/−, and LMNA^+/G609G/Prf1^+/+ mice from both genders underwent a survival test. a Kaplan–Meier curves of LMNA^+/G609G/Prf1^−/− mice, LMNA^+/G609G/Prf1^+/− mice and LMNA^+/G609G/Prf1^+/+ mice. Chi square Gehan–Breslow-Wilcoxon test was used for statistical analysis. Additional cohorts of LMNA^+/G609G/Prf1^+/+, LMNA^+/G609G/Prf1^−/−, ABT-737-treated and Vehicle-treated LMNA^+/G609G/Prf1^−/− female mice were raised. b Scheme of drug administration to LMNA^+/G609G/Prf1^−/− mice. Starting the age of 7 months ABT-737 or DMSO-based vehicle solution was administered to LMNA^+/G609G/Prf1^−/− female mice as described above. At the age of 11 months, mice from all groups were sacrificed and selected organs examined for the presence of senescent cells. c Representative images depicting SA-β-Gal activity in frozen sections of livers, pancreas, lungs, and skin from all groups of mice at the age of 11 months. Scale bar, 100 µm. d Percentage of SA-β-Gal + cells in livers, pancreas, lungs, and skin from all groups of mice. (n = 4 mice per group). e Representative images depicting immunofluorescence staining of p65 in livers from all mice groups. Scale bar, 100 µm. f Percentage of p65 + nuclei in livers from all groups. (n = 4 mice per group). g White blood cell counts of mice from all groups. (n = 4 mice per group). h Spleen weights of from all mice groups. (n = 4 mice per group). i Percentage of fibrotic area in livers paraffin-embedded sections of 11 month mice from all groups. (n = 4 mice per group). For all graphs, values are means ± SEM. Student’s t-test was used for all comparisons between mice groups. j Kaplan–Meier survival curves of ABT-737-treated and vehicle-treated LMNA^+/G609G/Prf1^−/− mice. Data is shown for males (n = 6), females (n = 5), and both genders combined (n = 11). Chi square Gehan–Breslow–Wilcoxon test was used for statistical analysis. (*P < 0.05, **P < 0.01, ***P < 0.001)